InflaRx N.V. filings document foreign-private-issuer reporting for a Nasdaq-listed biopharmaceutical company focused on complement-targeted anti-inflammatory therapeutics. Form 6-K reports furnish interim financial statements, management discussion and analysis, press releases on izicopan and vilobelimab programs, Nasdaq compliance notices, annual general meeting materials and shareholder voting results.
The company’s regulatory records also describe capital-structure matters, including ordinary-share offerings under an effective Form F-3 shelf registration statement and incorporation by reference into Form S-8 registration statements. Governance disclosures cover Dutch statutory annual accounts, audit instructions, director reappointments, board authorization matters and related shareholder approvals.
InflaRx N.V. 13G group filing: multiple Farallon entities and associated individuals report shared voting and dispositive power over disclosed Ordinary Shares (CUSIP N44821101). The filing lists per-entity share holdings and percentages (for example, Farallon Partners, L.L.C. 7,307,250 shares, 5%; certain Farallon individual reporting persons 7,500,000 shares, 5.1%). The Reporting Persons state the Shares are held directly by the Farallon Funds, file pursuant to Section 240.13d-1(c), and include a joint acquisition statement; the Reporting Persons neither disclaim nor affirm the existence of a group and also include express disclaimers of beneficial ownership by certain general partner and individual entities.
InflaRx N.V. ownership disclosure: TCG Crossover III entities and Chen Yu report shared beneficial ownership of 14,500,000 shares of Ordinary Shares, representing 9.8% of the class. The filing states 147,292,859 shares outstanding as of May 7, 2026, following an underwritten offering that closed on that date.
The shares are held of record by TCG Crossover III; voting and dispositive power is shared among TCG Crossover GP III and Chen Yu as described in the cover comments. The joint filing agreement and customary disclaimers of group status are included.
InflaRx N.V. completed an underwritten public offering of 75,000,000 ordinary shares at an offering price of $2.00 per share, generating gross proceeds of approximately $150 million before underwriting discounts and expenses.
The transaction was executed under InflaRx’s effective shelf registration statement on Form F-3, using a prospectus supplement dated May 6, 2026. Guggenheim Securities, LLC acted as representative of the underwriters under an Underwriting Agreement that includes customary representations and an indemnification of the underwriters for certain Securities Act liabilities.
InflaRx N.V. is offering 75,000,000 ordinary shares at $2.00 per share in a registered primary offering, implying aggregate gross proceeds of $150,000,000. Delivery is expected on May 7, 2026. The company estimates net proceeds of approximately $140.5 million, which it intends to use to advance its pipeline and for working capital and general corporate purposes.
The prospectus supplement discloses that shares outstanding would be 147,292,859 ordinary shares immediately after the offering, based on 72,292,859 ordinary shares outstanding as of March 31, 2026. InflaRx reported total funds available of approximately €39.7 million as of March 31, 2026 and states a projected cash runway through 2029 including the offering proceeds. The supplement highlights a strategic refocus toward development of izicopan and recent non-clinical data comparing reactive metabolite formation versus a comparator.
InflaRx N.V. files a preliminary prospectus supplement to offer ordinary shares on Nasdaq, describing terms, use of proceeds and updated corporate plans. The company highlights its lead program izicopan and reports new non‑clinical data (May 2026) suggesting lower reactive metabolite formation versus avacopan in human liver microsomes.
As of March 31, 2026, total funds available were approximately €39.7 million (cash €15.0 million; marketable securities €24.7 million), and shares outstanding were 72,292,859. Management stated a projected cash runway through 2029, including proceeds from this offering. The supplement discloses a Chief Medical Officer resignation effective August 2026, PFIC status likelihood for 2021–2025, and customary Dutch and U.S. tax discussions.
InflaRx N.V. files a preliminary prospectus supplement to offer ordinary shares on Nasdaq, describing terms, use of proceeds and updated corporate plans. The company highlights its lead program izicopan and reports new non‑clinical data (May 2026) suggesting lower reactive metabolite formation versus avacopan in human liver microsomes.
As of March 31, 2026, total funds available were approximately €39.7 million (cash €15.0 million; marketable securities €24.7 million), and shares outstanding were 72,292,859. Management stated a projected cash runway through 2029, including proceeds from this offering. The supplement discloses a Chief Medical Officer resignation effective August 2026, PFIC status likelihood for 2021–2025, and customary Dutch and U.S. tax discussions.
InflaRx N.V. is refocusing its pipeline around izicopan, an oral C5a receptor inhibitor, with Phase 2 planning underway in ANCA-associated vasculitis (AAV), a life-threatening kidney disease. The company aims to explore an expedited Phase 2/3 path to reach the commercial market faster.
InflaRx also plans open-label proof-of-concept studies for izicopan in complement‑mediated renal disorders, including atypical hemolytic uremic syndrome (aHUS), IgA nephropathy (IgAN) and C3 glomerulopathy (C3G), with clinical data expected next year and a pharmacokinetic bridging study in China this year.
The company believes izicopan’s pharmacology, safety and dosing profile could outperform the marketed comparator avacopan and estimates having sufficient funds to advance current development plans, including Phase 2 data in AAV and proof‑of‑concept readouts in aHUS, IgAN and C3G, and to support operations through 2029. Further hidradenitis suppurativa development, where market potential is projected above $1.5 billion annually, is currently envisaged only with a partner.
InflaRx N.V. is refocusing its pipeline around izicopan, an oral C5a receptor inhibitor, with Phase 2 planning underway in ANCA-associated vasculitis (AAV), a life-threatening kidney disease. The company aims to explore an expedited Phase 2/3 path to reach the commercial market faster.
InflaRx also plans open-label proof-of-concept studies for izicopan in complement‑mediated renal disorders, including atypical hemolytic uremic syndrome (aHUS), IgA nephropathy (IgAN) and C3 glomerulopathy (C3G), with clinical data expected next year and a pharmacokinetic bridging study in China this year.
The company believes izicopan’s pharmacology, safety and dosing profile could outperform the marketed comparator avacopan and estimates having sufficient funds to advance current development plans, including Phase 2 data in AAV and proof‑of‑concept readouts in aHUS, IgAN and C3G, and to support operations through 2029. Further hidradenitis suppurativa development, where market potential is projected above $1.5 billion annually, is currently envisaged only with a partner.
InflaRx N.V. reported a Q1 2026 net loss of €5.6 million, improving from a €8.3 million loss a year earlier, as it restructures and pivots resources toward its oral C5aR inhibitor izicopan.
Operating expenses fell to €7.5 million from €13.5 million, driven by sharply lower sales and marketing and reduced research and development and general and administrative costs, including lower share-based payments. GOHIBIC (vilobelimab) U.S. sales were discontinued, so the company recorded no revenue or cost of sales in the quarter.
Net financial income of €1.6 million reflected warrant revaluation gains and favorable foreign exchange. Cash and cash equivalents were €15.0 million and marketable securities €24.7 million, for total funds of about €39.7 million. Management believes this will fund operations into 2027, yet the company states that a material uncertainty exists that may cast significant doubt on its ability to continue as a going concern, given ongoing losses and planned clinical development spending.
InflaRx N.V. reported a Q1 2026 net loss of €5.6 million, improving from a €8.3 million loss a year earlier, as it restructures and pivots resources toward its oral C5aR inhibitor izicopan.
Operating expenses fell to €7.5 million from €13.5 million, driven by sharply lower sales and marketing and reduced research and development and general and administrative costs, including lower share-based payments. GOHIBIC (vilobelimab) U.S. sales were discontinued, so the company recorded no revenue or cost of sales in the quarter.
Net financial income of €1.6 million reflected warrant revaluation gains and favorable foreign exchange. Cash and cash equivalents were €15.0 million and marketable securities €24.7 million, for total funds of about €39.7 million. Management believes this will fund operations into 2027, yet the company states that a material uncertainty exists that may cast significant doubt on its ability to continue as a going concern, given ongoing losses and planned clinical development spending.
InflaRx N.V. reported new preclinical data showing its oral C5aR1 inhibitor izicopan generated low levels of reactive metabolites in a head-to-head in vitro study using human liver microsomes. In a glutathione trapping assay at 10 µM over 0–40 minutes, izicopan’s conjugate levels remained low, suggesting limited bioactivation in this experimental setting.
Under the same conditions, the marketed C5aR1 inhibitor avacopan produced higher levels of thiol adducts, with total reactive conjugate peak areas exceeding 100-fold those of izicopan at 5 and 10 minutes and about 10-fold at 20 and 40 minutes. InflaRx highlights these findings, together with prior Phase 1 and Phase 2a data and ≥90% C5a-induced neutrophil activation blockade over 14 days, as supporting izicopan’s differentiated profile, while emphasizing that in vitro results do not directly predict clinical outcomes.
InflaRx N.V. has regained compliance with Nasdaq’s minimum bid price requirement, removing a prior listing deficiency. Nasdaq confirmed that the company’s ordinary shares closed at $1.00 per share or higher for 10 consecutive business days from April 13 to April 24, 2026, satisfying Listing Rule 5450(a)(1). The earlier notice had given InflaRx until September 7, 2026 to cure the deficiency, but Nasdaq now considers the matter closed and the company’s listing status restored to good standing.
InflaRx N.V. reported that shareholders approved all agenda items at the April 23, 2026 Annual General Meeting. Approvals included the Dutch statutory annual accounts for the year ended December 31, 2025 and the appointment of KPMG Accountants N.V. as external auditor for 2026.
Shareholders granted the board continued authority to issue shares, grant rights to subscribe for shares, limit or exclude pre-emption rights, and acquire shares and depository receipts. They also approved multiple director re-appointments, an amendment to the articles of association, and a new Long-Term Incentive Plan, LTIP 2026.